{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:24:45Z","timestamp":1769804685060,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society of the Promotion of Science","doi-asserted-by":"crossref","award":["20K18352"],"award-info":[{"award-number":["20K18352"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34244-4","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:54:43Z","timestamp":1767171283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pluripotent epigenetic regulator OBP-801 attenuates fibrosis and maintains lower intraocular pressure in a rabbit PRESERFLO MicroShunt surgery model"],"prefix":"10.1038","volume":"16","author":[{"given":"Yusuke","family":"Koga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ikushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Sotozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"34244_CR1","doi-asserted-by":"publisher","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study & the GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020. Eye (Lond) 38, 2036-2046. https:\/\/doi.org\/10.1038\/s41433-024-02995-5 (2024).","DOI":"10.1038\/s41433-024-02995-5"},{"key":"34244_CR2","first-page":"705","volume":"124","author":"M Honjo","year":"2020","unstructured":"Honjo, M., Sakata, R., Fujishiro, T., Shirato, S. & Aihara, M. One-year postoperative outcomes of filtration minimally invasive glaucoma surgery using the PRESERFLO MicroShunt for primary open angle glaucoma in Japanese patients. J. Jpn. Ophthalmol. Soc. 124, 705\u2013712 (2020).","journal-title":"J. Jpn. Ophthalmol. Soc."},{"key":"34244_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/ijg.0000000000001734","volume":"30","author":"JF Batlle","year":"2021","unstructured":"Batlle, J. F., Corona, A. & Albuquerque, R. Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study. J. Glaucoma 30, 281\u2013286. https:\/\/doi.org\/10.1097\/ijg.0000000000001734 (2021).","journal-title":"J. Glaucoma"},{"key":"34244_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ogla.2021.07.008","volume":"5","author":"HJM Beckers","year":"2022","unstructured":"Beckers, H. J. M. et al. Safety and effectiveness of the PRESERFLO MicroShunt in primary open-angle glaucoma: Results from a 2-year multicenter study. Ophthalmol. Glaucoma 5, 195\u2013209. https:\/\/doi.org\/10.1016\/j.ogla.2021.07.008 (2022).","journal-title":"Ophthalmol. Glaucoma"},{"key":"34244_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vision6010012","volume":"6","author":"G Gambini","year":"2022","unstructured":"Gambini, G. et al. PreserFlo MicroShunt: An overview of this minimally invasive device for open-angle glaucoma. Vision (Basel) 6, 12. https:\/\/doi.org\/10.3390\/vision6010012 (2022).","journal-title":"Vision (Basel)"},{"key":"34244_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40662-022-00322-1","volume":"10","author":"IIK Ahmed","year":"2023","unstructured":"Ahmed, I. I. K., Sadruddin, O. & Panarelli, J. F. Subconjunctival filtration in evolution: Current evidence on MicroShunt implantation for treating patients with glaucoma. Eye Vis. (Lond) 10, 10. https:\/\/doi.org\/10.1186\/s40662-022-00322-1 (2023).","journal-title":"Eye Vis. (Lond)"},{"key":"34244_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ogla.2023.04.002","volume":"6","author":"JJ Armstrong","year":"2023","unstructured":"Armstrong, J. J., De Francesco, T., Ma, J., Schlenker, M. B. & Ahmed, I. I. K. Ab externo SIBS microshunt with mitomycin C for open-angle glaucoma: Three-year results as a primary surgical intervention. Ophthalmol. Glaucoma 6, 480\u2013492. https:\/\/doi.org\/10.1016\/j.ogla.2023.04.002 (2023).","journal-title":"Ophthalmol. Glaucoma"},{"key":"34244_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2023.09.023","volume":"131","author":"JF Panarelli","year":"2024","unstructured":"Panarelli, J. F. et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: Two-year results from a randomized, multicenter study. Ophthalmology 131, 266\u2013276. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.023 (2024).","journal-title":"Ophthalmology"},{"key":"34244_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ophtha.2013.11.025","volume":"121","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto, T. et al. The 5-year incidence of bleb-related infection and its risk factors after filtering surgeries with adjunctive mitomycin C: collaborative bleb-related infection incidence and treatment study 2. Ophthalmology 121, 1001\u20131006. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.025 (2014).","journal-title":"Ophthalmology"},{"key":"34244_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mam.2016.10.001","volume":"54","author":"S O'Reilly","year":"2017","unstructured":"O\u2019Reilly, S. Epigenetics in fibrosis. Mol. Aspects Med. 54, 89\u2013102. https:\/\/doi.org\/10.1016\/j.mam.2016.10.001 (2017).","journal-title":"Mol. Aspects Med."},{"key":"34244_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1124\/jpet.110.168385","volume":"335","author":"M Pang","year":"2010","unstructured":"Pang, M. & Zhuang, S. Histone deacetylase: A potential therapeutic target for fibrotic disorders. J. Pharmacol. Exp. Ther. 335, 266\u2013272. https:\/\/doi.org\/10.1124\/jpet.110.168385 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"34244_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/cs20120504","volume":"124","author":"J Tang","year":"2013","unstructured":"Tang, J., Yan, H. & Zhuang, S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci. (Lond) 124, 651\u2013662. https:\/\/doi.org\/10.1042\/cs20120504 (2013).","journal-title":"Clin. Sci. (Lond)"},{"key":"34244_CR13","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1167\/iovs.08-2919","volume":"50","author":"A Sharma","year":"2009","unstructured":"Sharma, A., Mehan, M. M., Sinha, S., Cowden, J. W. & Mohan, R. R. Trichostatin a inhibits corneal haze in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 50, 2695\u20132701. https:\/\/doi.org\/10.1167\/iovs.08-2919 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34244_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3892\/ijo.2013.2042","volume":"43","author":"T Yamada","year":"2013","unstructured":"Yamada, T. et al. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int. J. Oncol. 43, 1080\u20131086. https:\/\/doi.org\/10.3892\/ijo.2013.2042 (2013).","journal-title":"Int. J. Oncol."},{"key":"34244_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ygyno.2013.02.008","volume":"129","author":"T Yoshioka","year":"2013","unstructured":"Yoshioka, T., Yogosawa, S., Yamada, T., Kitawaki, J. & Sakai, T. Combination of a novel HDAC inhibitor OBP-801\/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Gynecol. Oncol. 129, 425\u2013432. https:\/\/doi.org\/10.1016\/j.ygyno.2013.02.008 (2013).","journal-title":"Gynecol. Oncol."},{"key":"34244_CR16","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1158\/1535-7163.Mct-16-0010","volume":"15","author":"S Toriyama","year":"2016","unstructured":"Toriyama, S. et al. A histone deacetylase inhibitor, OBP-801, and celecoxib synergistically inhibit the cell growth with apoptosis via a DR5-dependent pathway in bladder cancer cells. Mol. Cancer Ther. 15, 2066\u20132075. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0010 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"34244_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3727\/096504017x14850164661097","volume":"25","author":"M Akiyama","year":"2017","unstructured":"Akiyama, M. et al. Three combined treatments, a novel HDAC inhibitor OBP-801\/YM753, 5-fluorouracil, and paclitaxel, induce G2 phase arrest through the p38 pathway in human ovarian cancer cells. Oncol. Res. 25, 1245\u20131252. https:\/\/doi.org\/10.3727\/096504017x14850164661097 (2017).","journal-title":"Oncol. Res."},{"key":"34244_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-018-4815-x","volume":"171","author":"H Ono","year":"2018","unstructured":"Ono, H. et al. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Breast Cancer Res. Treat. 171, 43\u201352. https:\/\/doi.org\/10.1007\/s10549-018-4815-x (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"34244_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3892\/or.2018.6813","volume":"41","author":"C Tomoyasu","year":"2019","unstructured":"Tomoyasu, C. et al. OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells. Oncol. Rep. 41, 643\u2013649. https:\/\/doi.org\/10.3892\/or.2018.6813 (2019).","journal-title":"Oncol. Rep."},{"key":"34244_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15159","volume":"64","author":"D Kaneda","year":"2022","unstructured":"Kaneda, D. et al. The histone deacetylase inhibitor OBP-801 has in vitro\/in vivo anti-neuroblastoma activity. Pediatr. Int. 64, e15159. https:\/\/doi.org\/10.1111\/ped.15159 (2022).","journal-title":"Pediatr. Int."},{"key":"34244_CR21","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.3390\/cancers16234058","volume":"16","author":"T Narukawa","year":"2024","unstructured":"Narukawa, T. et al. The novel HDAC inhibitor OBP-801 promotes MHC class I presentation through LMP2 upregulation, enhancing the PD-1-targeting therapy in clear cell renal cell carcinoma. Cancers (Basel) 16, 4058. https:\/\/doi.org\/10.3390\/cancers16234058 (2024).","journal-title":"Cancers (Basel)"},{"key":"34244_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s10637-021-01180-9","volume":"40","author":"EI Heath","year":"2022","unstructured":"Heath, E. I. et al. Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Invest. New Drugs 40, 300\u2013307. https:\/\/doi.org\/10.1007\/s10637-021-01180-9 (2022).","journal-title":"Invest. New Drugs"},{"key":"34244_CR23","doi-asserted-by":"publisher","first-page":"20936","DOI":"10.1038\/s41598-020-77811-7","volume":"10","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto, Y. et al. Pluripotent epigenetic regulator OBP-801 maintains filtering blebs in glaucoma filtration surgery model. Sci. Rep. 10, 20936. https:\/\/doi.org\/10.1038\/s41598-020-77811-7 (2020).","journal-title":"Sci. Rep."},{"key":"34244_CR24","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1167\/iovs.15-18750","volume":"57","author":"A Sharma","year":"2016","unstructured":"Sharma, A. et al. Epigenetic modification prevents excessive wound healing and scar formation after glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 57, 3381\u20133389. https:\/\/doi.org\/10.1167\/iovs.15-18750 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34244_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00109-018-1722-x","volume":"97","author":"LF Seet","year":"2019","unstructured":"Seet, L. F., Toh, L. Z., Finger, S. N., Chu, S. W. L. & Wong, T. T. Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva. J. Mol. Med. (Berl) 97, 63\u201375. https:\/\/doi.org\/10.1007\/s00109-018-1722-x (2019).","journal-title":"J. Mol. Med. (Berl)"},{"key":"34244_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/tvst.11.1.30","volume":"11","author":"LF Seet","year":"2022","unstructured":"Seet, L. F. et al. Effects of valproic acid and mitomycin C combination therapy in a rabbit model of minimally invasive glaucoma surgery. Transl. Vis. Sci. Technol. 11, 30. https:\/\/doi.org\/10.1167\/tvst.11.1.30 (2022).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"34244_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1136\/bjophthalmol-2020-318691","volume":"106","author":"ZL Yap","year":"2022","unstructured":"Yap, Z. L. et al. Effect of valproic acid on functional bleb morphology in a rabbit model of minimally invasive surgery. Br. J. Ophthalmol. 106, 1028\u20131036. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318691 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"34244_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbrc.2021.01.060","volume":"544","author":"H Hatanaka","year":"2021","unstructured":"Hatanaka, H. et al. Epigenetic regulation of the epithelial mesenchymal transition induced by synergistic action of TNF-\u03b1 and TGF-\u03b2 in retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 544, 31\u201337. https:\/\/doi.org\/10.1016\/j.bbrc.2021.01.060 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"34244_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1167\/tvst.9.11.23","volume":"9","author":"J Swogger","year":"2020","unstructured":"Swogger, J. et al. Injected versus sponge-applied mitomycin C (MMC) during modified trabeculectomy in New Zealand white rabbit model. Transl. Vis. Sci. Technol. 9, 23. https:\/\/doi.org\/10.1167\/tvst.9.11.23 (2020).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"34244_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17434440.2018.1419060","volume":"15","author":"A Chaudhary","year":"2018","unstructured":"Chaudhary, A., Salinas, L., Guidotti, J., Mermoud, A. & Mansouri, K. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev. Med. Devices 15, 47\u201359. https:\/\/doi.org\/10.1080\/17434440.2018.1419060 (2018).","journal-title":"Expert Rev. Med. Devices"},{"key":"34244_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00061198-200412000-00005","volume":"13","author":"AP Wells","year":"2004","unstructured":"Wells, A. P. et al. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J. Glaucoma 13, 454\u2013460. https:\/\/doi.org\/10.1097\/00061198-200412000-00005 (2004).","journal-title":"J. Glaucoma"},{"key":"34244_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.10.9.9","volume":"10","author":"T Fujimoto","year":"2021","unstructured":"Fujimoto, T. et al. Intraocular pressure-lowering effects of trabeculectomy versus MicroShunt insertion in rabbit eyes. Transl. Vis. Sci. Technol. 10, 9. https:\/\/doi.org\/10.1167\/tvst.10.9.9 (2021).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"34244_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000076891","volume":"36","author":"CJ Liu","year":"2004","unstructured":"Liu, C. J., Huang, Y. L., Chiu, A. W. & Ju, J. P. Transcript expression of matrix metalloproteinases in the conjunctiva following glaucoma filtration surgery in rabbits. Ophthalmic Res. 36, 114\u2013119. https:\/\/doi.org\/10.1159\/000076891 (2004).","journal-title":"Ophthalmic Res."},{"key":"34244_CR34","first-page":"4799","volume":"8","author":"W Ran","year":"2015","unstructured":"Ran, W., Zhu, D. & Feng, Q. TGF-\u03b22 stimulates Tenon\u2019s capsule fibroblast proliferation in patients with glaucoma via suppression of miR-29b expression regulated by Nrf2. Int. J. Clin. Exp. Pathol. 8, 4799\u20134806 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"34244_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1167\/iovs.16-21163","volume":"58","author":"H Shi","year":"2017","unstructured":"Shi, H. et al. Losartan attenuates scar formation in filtering bleb after trabeculectomy. Invest. Ophthalmol. Vis. Sci. 58, 1478\u20131486. https:\/\/doi.org\/10.1167\/iovs.16-21163 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34244_CR36","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1167\/iovs.18-26526","volume":"60","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Rosiglitazone treatment prevents postoperative fibrosis in a rabbit model of glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 60, 2743\u20132752. https:\/\/doi.org\/10.1167\/iovs.18-26526 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34244_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.64.10.2","volume":"64","author":"M Yoshida","year":"2023","unstructured":"Yoshida, M. et al. DPP-4 inhibitors attenuate fibrosis after glaucoma filtering surgery by suppressing the TGF-\u03b2\/Smad signaling pathway. Invest. Ophthalmol. Vis. Sci. 64, 2. https:\/\/doi.org\/10.1167\/iovs.64.10.2 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34244_CR38","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41598-024-52359-y","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee, J., Honjo, M. & Aihara, M. A MEK inhibitor arrests the cell cycle of human conjunctival fibroblasts and improves the outcome of glaucoma filtration surgery. Sci. Rep. 14, 1871. https:\/\/doi.org\/10.1038\/s41598-024-52359-y (2024).","journal-title":"Sci. Rep."},{"key":"34244_CR39","doi-asserted-by":"publisher","first-page":"Cd001132","DOI":"10.1002\/14651858.CD001132.pub2","volume":"2014","author":"E Green","year":"2014","unstructured":"Green, E., Wilkins, M., Bunce, C. & Wormald, R. 5-Fluorouracil for glaucoma surgery. Cochrane Database Syst. Rev. 2014, Cd001132. https:\/\/doi.org\/10.1002\/14651858.CD001132.pub2 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"34244_CR40","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/jcph.2451","volume":"64","author":"GD Novack","year":"2024","unstructured":"Novack, G. D. & Robin, A. L. Ocular pharmacology. J. Clin. Pharmacol. 64, 1068\u20131082. https:\/\/doi.org\/10.1002\/jcph.2451 (2024).","journal-title":"J. Clin. Pharmacol."},{"key":"34244_CR41","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1001\/archopht.124.12.1742","volume":"124","author":"AC Acosta","year":"2006","unstructured":"Acosta, A. C. et al. A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): Biocompatibility and function in normal rabbit eyes. Arch. Ophthalmol. 124, 1742\u20131749. https:\/\/doi.org\/10.1001\/archopht.124.12.1742 (2006).","journal-title":"Arch. Ophthalmol."},{"key":"34244_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.survophthal.2012.01.008","volume":"57","author":"LK Seibold","year":"2012","unstructured":"Seibold, L. K., Sherwood, M. B. & Kahook, M. Y. Wound modulation after filtration surgery. Surv. Ophthalmol. 57, 530\u2013550. https:\/\/doi.org\/10.1016\/j.survophthal.2012.01.008 (2012).","journal-title":"Surv. Ophthalmol."},{"key":"34244_CR43","doi-asserted-by":"publisher","first-page":"35187","DOI":"10.1038\/srep35187","volume":"6","author":"D Ma","year":"2016","unstructured":"Ma, D. et al. Repeatability, reproducibility and agreement of intraocular pressure measurement in rabbits by the TonoVet and Tono-Pen. Sci. Rep. 6, 35187. https:\/\/doi.org\/10.1038\/srep35187 (2016).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34244-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:58:56Z","timestamp":1769767136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34244-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34244"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34244-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.U. is the President and CEO of Oncolys BioPharma, Inc., the manufacturer of OBP. M.U. received research support from Oncolys BioPharma, Inc. and from Santen Pharmaceutical Co., Ltd. The other authors have no real or potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and the study protocols were approved by the Animal Use Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan (approval no. B2021-105). The study is reported in accordance with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"4124"}}